B. Riley Issues Pessimistic Forecast for Lantheus (NASDAQ:LNTH) Stock Price

Lantheus (NASDAQ:LNTH) had its target price decreased by B. Riley from $127.00 to $122.00 in a research note issued to investors on Friday morning,Benzinga reports. B. Riley currently has a buy rating on the medical equipment provider’s stock.

A number of other equities analysts also recently issued reports on LNTH. Truist Financial raised their price objective on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group began coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Finally, JMP Securities restated a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Trading Down 1.2 %

LNTH opened at $97.71 on Friday. Lantheus has a 1-year low of $57.92 and a 1-year high of $126.89. The company has a market cap of $6.69 billion, a P/E ratio of 16.26 and a beta of 0.38. The company’s 50 day moving average is $92.67 and its 200-day moving average is $96.64.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities analysts forecast that Lantheus will post 6.01 EPS for the current year.

Insiders Place Their Bets

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lantheus

Several large investors have recently bought and sold shares of the stock. Janus Henderson Group PLC raised its holdings in shares of Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after purchasing an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after buying an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after acquiring an additional 435,445 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Lantheus during the 4th quarter worth $36,183,000. Finally, Groupama Asset Managment purchased a new stake in Lantheus during the third quarter worth about $439,000. 99.06% of the stock is currently owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.